OKYO Pharma’s Chief Medical Officer Buys Shares Amid Anticipated Phase‑3 Trial Launch

Insider Buying Continues Amid Volatile Valuation On July 21 2026, Chief Medical Officer Flavio Mantelli purchased 20 000 shares of OKYO Pharma at $1.40, a modest 0.06% rise above the close of $1.44. While the trade represents only 0.03 % of the company’s market cap, it comes on the heels of a substantial purchase by Chairman Gabriele Cerrone, who now owns roughly 10.85 million shares. Together, the two insiders control about 15 % of the outstanding capital, a concentration that can signal confidence—or an attempt to influence short‑term liquidity.

What This Means for Investors OKYO’s share price is trading near its 52‑week low of $1.34, after a 44.9 % decline this year. The negative P/E ratio of –12.03 and the recent 2 % weekly gain suggest a stock that is still highly speculative. Mantelli’s purchase, however, arrives at a moment of heightened media buzz (10.16 % intensity) and a slightly positive sentiment (+9). For rational investors, this may indicate that the medical leadership is more bullish than the market, perhaps anticipating a breakthrough in its Phase‑3 trial for neuropathic corneal pain. Yet the short‑term volatility remains a risk; any delay or regulatory setback could trigger a sharper slide, while a positive trial outcome could ignite a rally.

Mantelli’s Insider Profile Mantelli’s transaction history shows a consistent pattern of holding options rather than trading shares. The 2026–2030 series of 3‑forms reveal no actual share purchases, only option holdings at zero cost. This suggests a cautious, long‑term stance: he retains the right to buy shares at a predetermined price, signaling belief in future upside without committing cash now. The recent share purchase is therefore notable; it may reflect a short‑term liquidity need or a strategic move to align ownership with upcoming funding rounds. Compared to other insiders, Mantelli’s activity is relatively low‑profile, but his position as Chief Medical Officer gives him visibility on the scientific pipeline, potentially making his trades more meaningful to stakeholders.

Strategic Outlook OKYO is set to launch a global Phase‑3 trial later this year, and the company will present interim data at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22. If the trial shows efficacy, the company could face a significant funding requirement. Insider buying—particularly from the medical leadership—may help bridge that gap by signaling confidence to investors. However, the company’s valuation remains fragile; investors should monitor both clinical milestones and any changes in insider holdings, as these can presage shifts in market sentiment.